Acellular Pertussis Vaccine Symposium
November 12 - 14, 2000
Bethesda, Maryland
Agenda Purpose: This meeting will present data from acellular pertussis studies. Participants will discuss new public health issues about the use of this vaccine (e.g. the use in other age groups and populations) based on current clinical trials information.
Meeting Goals: 1) Evaluate safety and effectiveness of different acellular pertussis vaccines in specific populations; 2) Examine alternatives to existing schedules; and 3) Evaluate the duration of immunity and efficacy following a primary series.
Sunday, November 12
Surveillance and Epidemiological Data
- 8:45 a.m. - 9:00 a.m.
Opening Remarks and Welcome, Carole Heilman and David Klein
- 9:00 a.m. - 9:20 a.m.
Use of Pertussis Vaccines on a Global Scale, Jean Marc Olive
- 9:20 a.m. - 9:40 a.m.
United States Surveillance Data Since Licensure in 1996, Trudy Murphy
- 9:40 a.m. - 10:00 a.m.
Canadian Surveillance and Epidemiological Data, Scott Halperin
- 10:00 a.m. - 10:30 a.m.
Break
- 10:30 a.m. - 10:50 a.m.
Global Diphtheria Epidemiology and Correlates of Disease, Melinda Wharton
- 10:50 a.m. - 11:10 a.m.
Status of Pertussis Diagnostic Tools, Carl Wirsing von Konig
- 11:10 a.m. - 11:30 a.m.
Summary of the "WHO Global Pertussis Surveillance Meeting," Mark Laforce
- 11:30 a.m. - 12:00 p.m.
Discussion
- 12:00 p.m. - 1:30 p.m.
Lunch
Top of Page
Clinical Experience in Infanst Post Licensure: Safety Profiles and Duration
of Immunity and Efficacy for DTaP
- 1:30 p.m. - 2:00 p.m.
Long-Term Efficacy of Biken Acellular Pertussis Vaccine, Johannes Liese
- 2:00 p.m. - 2:30 p.m.
Wyeth-Lederle Takeda Vaccine and Correlates of Protection, Ulrich Heininger
- 2:30 p.m. - 3:00 p.m.
Aventis Pasteur 2-Component Vaccine Used in Senegal, Francois Simondon
- 3:00 p.m. - 3:30 p.m.
Break
- 3:30 p.m. - 4:00 p.m.
Efficacy of Two 3-Component DTaP Vaccines Over Five Years of Follow-Up, Stefania Salmasso
- 4:00 p.m. - 4:30 p.m.
Experience With a NAVA Monovalent Vaccine, John Robbins
- 4:30 p.m. - 5:00 p.m.
Trial I and Trial II Follow-Up Data and Correlates of Protection, Patrick Olin
- 5:00 p.m. - 5:30 p.m.
Discussion
- 6:00 p.m. - 7:30 p.m.
Reception
Top of Page
Monday, November 13
Safety Data Associated with the Use of Acellular Pertussis Vaccines
- 9:00 a.m. - 9:20 a.m.
Surveillance and Testing of Children Who Experienced HHE in Stockholm Trial, Harald Heijbel
- 9:20 a.m. - 9:40 a.m.
Large-Linked Safety Data in the United States, Robert Chen
- 9:40 a.m. - 10:00 a.m.
Comparison of Local Adverse Events Following Booster Doses With Different Acellular
Vaccines, Margaret Rennels
- 10:00 a.m. - 10:20 a.m.
Canadian Data on Safety Following the Use of a DTaP Combination Vaccine in Infants, David Scheifele
- 10:20 a.m. - 10:40 a.m.
Break
- 10:20 a.m. - 11:00 a.m.
Impact of Scheduling on Safety and Antibody Outcomes for DTaP, Patrick Olin
- 11:00 a.m. - 11:20 a.m.
Safety Data Following Fourth and Fifth Doses of Wyeth-Lederle Takeda Vaccine in Erlangen
Trial, Ulrich Heininger
- 11:20 a.m. - 11:40 a.m.
Safety Data Following Fourth and Fifth Doses of Aventis Pasteur Biken Vaccine in Munich
Trial, Johannes Liese
- 11:40 a.m. - 12:00 p.m.
Reactogenicity of Booster Doses: Field Experience in Germany, Fred Zepp
- 12:00 p.m. - 12:20 p.m.
Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two 3-Component
DTaP Vaccines in Italy, Alberto Tozzi
- 12:20 p.m. - 12:50 p.m.
Discussion
- 12:50 p.m. - 2:00 p.m.
Lunch (on your own)
- 2:00 p.m. - 4:00 p.m.
Roundtable Discussion and Policy Issues, Participants to be Confirmed
Is there a need for five doses of acellular pertussis vaccine prior to school entry in the United States? What is the optimal childhood schedule? What are the consequences of adding or dropping a dose? What factors need to be considered when changing the schedule?
Is there a need for an adolescent and/or an adult dose? What are the concerns?
Is it possible to adopt a universal schedule for developed and developing countries?
What are the problems associated with the use of acellular vaccines as part of a combination vaccine package (i.e., need for a toddler HIV booster, immunogenicity problems, constraints imposed by combination products in countries that do not provide four doses of pertussis vaccines during the first two years of life)?
Are all acellular pertussis vaccines equal or do some offer specific advantages with regard to controlling infection and immunization strategies?
Will the use of adolescent/adult boosters change the epidemiology of pertussis disease?
- 4:00 p.m. - 4:20 p.m.
Break
Top of Page
Clinical Issues Relevant to Acellular Pertussis Vaccines
- 4:20 p.m. - 4:40 p.m.
Polymorphism in the Bordetella pertussis Population and Its Immunological Relevance, Fritz Mooi
- 4:40 p.m. - 5:00 p.m.
Molecular Epidemiological Data on Circulating Strains of Pertussis in the United States, Gary Sanden
- 5:00 p.m. - 5:20 p.m.
NHANES Serum Specimen Evaluation for Anti-FHA, -FIM2, 3, -PRN, and -PT,
Kris Bisgard/Drew Baughman
- 5:20 p.m. - 5:40 p.m.
Mucosal Immunization: New Approaches to Pertussis Vaccine Delivery, Kingston Mills
- 5:40 p.m. - 6:00 p.m.
Better Vaccines for the Future: New Candidate Antigens, Alison Weiss
- 6:00 p.m. - 6:30 p.m.
Discussion
Top of Page
Tuesday, November 14
Adult/Adolescent Pertussis Clinical Trials
- 9:00 a.m. - 9:20 a.m.
Background Incidence Data in the United States, Kathryn Edwards
- 9:20 a.m. - 10:30 a.m.
NIAID Multicenter Adult/Adolescent Pertussis Efficacy Study, Joel Ward
- 10:30 a.m. - 10:50 a.m.
Break
- 10:50 a.m. - 11:10 a.m.
The Increasing Incidence of Pertussis in Massachusetts Adolescents and Adults, Colin Marchant
- 11:10 a.m. - 11:30 a.m.
Human Challenge Studies, Sylvia Yeh
- 11:30 a.m. - 12:00 p.m.
Discussion
- 12:00 p.m. - 12:05 p.m.
Closing Remarks and Adjourn, David Klein
Top of Page
Contact: Tom Carrier
IQ Solutions, Inc.
Telephone: (301) 984-1471
|
